Novartis AG (ADR) (NVS), Sanofi SA (ADR) (SNY): Pharma Big Wigs Warm Up to Africa’s $40 Billion Opportunity

Page 1 of 2

For a long time, Africa’s traditional enemy with regard to diseases have been communicable diseases like HIV and Malaria. Now, however, this trend is changing. Prevalence of HIV is on a downtrend and malaria infections in most parts of the continent have dropped significantly. On the flip side, however, non communicable diseases like cancer, high blood pressure, and diabetes are securing root.

The World Health Organization, along with other reputable global health organizations, contends that non communicable diseases accounted for 28% of all deaths in Sub Saharan Africa in 2008. This figure is expected to reach 46% by 2030. In view of this, pharmaceutical spending is expected to rise astronomically moving forward. In 2012, pharmaceutical spending in the continent stood at $18 billion. This figure is expected to reach $40 billion as early as 2020. A growing middle class, coupled with steady economic growth in most parts of the continent, will be the impetus behind the increased spending.

Novartis AG (ADR) (NYSE:NVS)

What does this mean for pharmaceutical big wigs, and in particular Novartis AG (ADR) (NYSE:NVS), Sanofi SA (ADR) (NYSE:SNY), and GlaxoSmithKline plc (ADR) (NYSE:GSK)?

GlaxoSmithKline takes volume over profit approach

Not exactly a hard-nosed business, but GlaxoSmithKline is seeking to increase its presence in the African market at the expense of its margins. GlaxoSmithKline plc (ADR) (NYSE:GSK)’s volume over profit approach, brought to light in mid 2012, has seen the company implement price cuts for some of its key drugs. The goal is to increase its volume five-fold over the next half decade. What’s more is that the initiative is not nested under the company’s charity unit, but has been absorbed into the core business.

As far as social responsibility goes, GlaxoSmithKline plc (ADR) (NYSE:GSK) gets a straight ten out of ten. Business-wise, however, the move has been deemed by watchers as not the wisest from the pharmaceutical heavyweight. In my view, deeming the move to be unwise is at the least myopic. Despite the floundering state of the economy in most parts of the African continent, growth is encouraging. In fact, economic growth over the past ten years in key African economies like Kenya and Nigeria has been between 4%-7%, which is much higher than growth in most developed economies.

This growth goes hand in hand with the rapid development of a strong middle class. In relation to this, more African consumers will have money to spend on the treatment and control of chronic non communicable illnesses moving forward. GlaxoSmithKline plc (ADR) (NYSE:GSK)’s move to enlarge its footprint now will certainly pay off in the long run. The fact that it is also moving its focus away from the austerity-hit Eurozone to emerging markets means that it will place its full weight behind the initiative.

Novartis seeks to enhance continent’s research and development

Novartis AG (ADR) (NYSE:NVS), on the other hand, is taking a slightly different approach. In February, it announced a joint initiative with The University Of Cape Town (UCT) that would help pass on the skills needed to treat communicable diseases, which, despite decreasing over the years, still remains a thorn in the flesh of African society. Under the joint initiative, Novartis AG (ADR) (NYSE:NVS) and UCT will enhance the skill set of African medical professionals and improve the continent’s Research and Development, which is critically important for health care. This collaboration will lead to the development of an FDA-level clinic study site in South Africa. The clinic will particularly work on medicines against Tuberculosis and facilitate research on malaria.

Through this move, Novartis AG (ADR) (NYSE:NVS) will not only be able to grow its investment in Africa moving forward, but it will also be able to give back to society. From my understanding, this will act as an incentive for distributors and by extension consumers, as well.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

10 Self-Made Billionaires Who Came From Nothing

The 10 Most Expensive Cities to Live in North America

The 13 Most Expensive Headphones in the World to Represent

The Top 20 Wealthiest Soccer Teams in 2014

4 BuzzWorthy Cannabis Stocks And Some Smoking Derivative Plays

The 10 Healthiest Fast Food Chains in America to Dine At

The 5 Most Expensive Cat Food Brands You Can Spoil Your Kitty With

The 6 Best eCommerce Platforms for Small Businesses

The 10 Worst Mistakes an Entrepreneur Can Make

The 5 Most OP Characters in League of Legends to Carry Games and Crush Foes With

The 5 Best Foods to Eat Before Running that Will Help You Pound the Pavement

10 Glaring Plot Holes in The Walking Dead that a Zombie-Filled Bus Could Drive Through

The 5 Biggest Celebrity Stoners Who Love Their Reefer

The 10 Most Overrated Movies Of All Time by Out-of-Touch Critics

Top 6 Least Expensive Cruise Destinations For 2015 that Will Take You to Paradise

10 States with Lowest Substance Abuse Rates in America

The 14 Most Watched TV Finales Ever

The 10 Best Selling Role Playing Games of All Time for PC

10 Most Influential Papers In Economics

Top 8 Biggest Charities in the US

10 Worst Celebrity Career Moves Ever

Top 10 Best Paid Tennis Stars in the World

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

How to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

10 Best Places to Visit in Central and South America

The 10 Greatest Empires in History Which Nearly Conquered the World

The 6 Cheapest Boarding Schools In America 2015

5 Clear Reasons LoL is Better than DotA, Continues to Rule MOBAs

The Only 9 Teams with a Chance to Win the Super Bowl

The 15 Most Common Phobias in America that Induce Fits of Panic

Top 6 Least Expensive Tourist Destinations in 2014

Jim Goetz, Peter Fenton, Jim Breyer: Top 6 Venture Investors for 2014

Top 15 Billionaires in 2014

5 Pitfalls To Avoid When Buying a Franchise

Top 20 Medical Schools in the US – 2014 Rankings

4 Business Strategies that Turned Jamie Oliver into the World’s Richest Chef

6 Qualities That Make You A Good Team Player

10 High Paying Seasonal Jobs in America this Holiday Season

The 10 Busiest Shipping Lanes in the World

5 Most Valuable Brands in China

The 10 States with Highest Substance Abuse Rates Crippling Their Populace

The Top 10 Things to Do Before You Die That Will Echo for Eternity

The 10 Best Selling Items on Etsy

Top 10 Things to Do in Tokyo, the Greatest City in the World

10 Mistakes on Social Media that Can Harm You and Will Probably Get You Canned

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!